Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hypoxia-inducible factor–prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease
Authors
Keywords
anemia, chronic kidney disease, erythropoietin, hepcidin, hypoxia-inducible factor, iron, prolyl hydroxylase domain dioxygenase
Journal
Kidney International Supplements
Volume 11, Issue 1, Pages 8-25
Publisher
Elsevier BV
Online
2021-03-19
DOI
10.1016/j.kisu.2020.12.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Iron metabolism and management: focus on chronic kidney disease
- (2021) Anil K. Agarwal Kidney International Supplements
- Treatment of anemia in difficult-to-manage patients with chronic kidney disease
- (2021) Ritesh Raichoudhury et al. Kidney International Supplements
- The Genomics and Genetics of Oxygen Homeostasis
- (2020) Gregg L. Semenza Annual Review of Genomics and Human Genetics
- Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia
- (2020) Tadao Akizawa et al. Clinical Journal of the American Society of Nephrology
- Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease
- (2020) Ughetta del Balzo et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan
- (2020) Tadao Akizawa et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- MO001ROXADUSTAT FOR THE TREATMENT OF ANAEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS: A PHASE 3, RANDOMISED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY
- (2020) Jonathan Barratt et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers
- (2019) John C. Chappell et al. JOURNAL OF CLINICAL INVESTIGATION
- Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
- (2019) Tadao Akizawa et al. ADVANCES IN THERAPY
- Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
- (2019) Nan Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
- (2019) Nan Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
- (2019) Tadao Akizawa et al. THERAPEUTIC APHERESIS AND DIALYSIS
- A 24‐week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients
- (2019) Yoshiharu Tsubakihara et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
- (2019) Neil S. Sanghani et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- The Impact of Anemia Treatment on Health-Related Quality of Life in Patients With Chronic Kidney Disease in the Contemporary Era
- (2019) Fredric O. Finkelstein et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor
- (2019) Kenji Fukui et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Mechanisms of hypoxia signalling: new implications for nephrology
- (2019) Johannes Schödel et al. Nature Reviews Nephrology
- The multifaceted role of iron in renal health and disease
- (2019) Rachel P. L. van Swelm et al. Nature Reviews Nephrology
- Now a Nobel gas: oxygen
- (2019) Joachim Fandrey et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor
- (2019) David F. Adams et al. TOXICOLOGIC PATHOLOGY
- A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis
- (2019) Christine K. Bailey et al. BMC Nephrology
- Oral roxadustat three times weekly in ESA‐naïve and ESA‐converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies
- (2019) Tadao Akizawa et al. THERAPEUTIC APHERESIS AND DIALYSIS
- A Mass Balance Study of 14 C‐Labeled JTZ‐951 (Enarodustat), a Novel Orally Available Erythropoiesis‐Stimulating Agent, in Patients With End‐Stage Renal Disease on Hemodialysis
- (2019) Sudhakar M. Pai et al. Clinical Pharmacology in Drug Development
- First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia
- (2018) M. Böttcher et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia
- (2018) Hartmut Beck et al. ChemMedChem
- Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Safety, and Tolerability of Roxadustat in Healthy Subjects
- (2018) Dorien Groenendaal-van de Meent et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Erythropoietic regulators of iron metabolism
- (2018) Tomas Ganz FREE RADICAL BIOLOGY AND MEDICINE
- Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects
- (2018) T. Shibata et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
- (2018) Volker H Haase et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- OUP accepted manuscript
- (2018) NEPHROLOGY DIALYSIS TRANSPLANTATION
- Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers
- (2018) Aya Shinfuku et al. AMERICAN JOURNAL OF NEPHROLOGY
- HIF-1α promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease
- (2018) Andre Kraus et al. KIDNEY INTERNATIONAL
- Anemia of inflammation
- (2018) Guenter Weiss et al. BLOOD
- Effects of Molidustat in the Treatment of Anemia in CKD
- (2018) Iain C. Macdougall et al. Clinical Journal of the American Society of Nephrology
- Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease
- (2017) Jing Liu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats
- (2017) James Beck et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver
- (2017) Seonghwan Hwang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
- (2017) Nan Chen et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
- (2017) Tzu-Lan Yeh et al. Chemical Science
- FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase
- (2017) Ingo Flamme et al. PLoS One
- A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial
- (2016) Richard A. Brigandi et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
- (2016) Robert Provenzano et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
- (2016) Tadao Akizawa et al. AMERICAN JOURNAL OF NEPHROLOGY
- Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD
- (2016) R. Provenzano et al. Clinical Journal of the American Society of Nephrology
- Hypoxia-dependent regulation of inflammatory pathways in immune cells
- (2016) Cormac T. Taylor et al. JOURNAL OF CLINICAL INVESTIGATION
- Increased Synthesis of Liver Erythropoietin with CKD
- (2016) S. de Seigneux et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease
- (2016) Pablo E. Pergola et al. KIDNEY INTERNATIONAL
- Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcification
- (2016) Sophie Mokas et al. KIDNEY INTERNATIONAL
- The Endothelial Prolyl-4-Hydroxylase Domain 2/Hypoxia-Inducible Factor 2 Axis Regulates Pulmonary Artery Pressure in Mice
- (2016) Pinelopi P. Kapitsinou et al. MOLECULAR AND CELLULAR BIOLOGY
- HIF2α–arginase axis is essential for the development of pulmonary hypertension
- (2016) Andrew S. Cowburn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats
- (2015) Terrance D Barrett et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects
- (2015) Katsutoshi Hara et al. Drug Metabolism and Pharmacokinetics
- Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia
- (2015) L. Holdstock et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
- (2015) A. Besarab et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Anaemia in kidney disease: harnessing hypoxia responses for therapy
- (2015) Mark J. Koury et al. Nature Reviews Nephrology
- Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
- (2015) Anatole Besarab et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Compression-induced HIF-1 enhances thrombosis and PAI-1 expression in mouse skin
- (2015) Maki Kaneko et al. WOUND REPAIR AND REGENERATION
- Identification of erythroferrone as an erythroid regulator of iron metabolism
- (2014) Léon Kautz et al. NATURE GENETICS
- Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases
- (2014) Holger K. Eltzschig et al. NATURE REVIEWS DRUG DISCOVERY
- Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects
- (2014) Ingo Flamme et al. PLoS One
- Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis
- (2013) Maria Lönnberg et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
- (2013) Ron T Gansevoort et al. LANCET
- Hepcidin and iron homeostasis
- (2012) Tomas Ganz et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis
- (2012) Qingdu Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Notice
- (2012) Kidney International Supplements
- Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia
- (2011) Guo-Min Shen et al. BIOCHEMICAL JOURNAL
- Regulation of hepcidin expression at high altitude
- (2011) N. P. Talbot et al. BLOOD
- Endogenous Erythropoietin and the Association with Inflammation and Mortality in Diabetic Chronic Kidney Disease
- (2011) M. Wagner et al. Clinical Journal of the American Society of Nephrology
- Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Müller cells
- (2011) M. Lin et al. DIABETOLOGIA
- Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis
- (2011) M. Mastrogiannaki et al. HAEMATOLOGICA
- Oxygen Sensing, Homeostasis, and Disease
- (2011) Gregg L. Semenza NEW ENGLAND JOURNAL OF MEDICINE
- Mammalian Per-Arnt-Sim Proteins in Environmental Adaptation
- (2010) Brian E. McIntosh et al. Annual Review of Physiology
- Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia
- (2010) P. P. Kapitsinou et al. BLOOD
- Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
- (2010) W. M. Bernhardt et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Iron supplementation to treat anemia in patients with chronic kidney disease
- (2010) Anatole Besarab et al. Nature Reviews Nephrology
- Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis
- (2009) P. S. Parfrey et al. Clinical Journal of the American Society of Nephrology
- Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin
- (2009) D. R. Ashby et al. HAEMATOLOGICA
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
- (2009) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence for a Lack of a Direct Transcriptional Suppression of the Iron Regulatory Peptide Hepcidin by Hypoxia-Inducible Factors
- (2009) Melanie Volke et al. PLoS One
- Immunoassay for human serum hepcidin
- (2008) T. Ganz et al. BLOOD
- Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease Patients
- (2008) F. O. Finkelstein et al. Clinical Journal of the American Society of Nephrology
- Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
- (2008) William G. Kaelin et al. MOLECULAR CELL
- Expanding chemical biology of 2-oxoglutarate oxygenases
- (2008) Christoph Loenarz et al. Nature Chemical Biology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search